Evidence & regulatory context
- Mechanism
- Cell-permeable itaconate derivative acting through KEAP1 alkylation / NRF2 activation and IRG1-itaconate immunometabolic signalling. No ChEMBL record under 'dimethyl itaconate'. No human trial of dimethyl itaconate or of 4-octyl itaconate; the 148 hits from the itaconate/fumarate query were dimethyl fumarate (Tecfidera/BG00012) studies, a different electrophilic ester, and were deliberately NOT recorded as translation evidence for itaconate.
- Target
- Not recorded
- Injury models
- Chemical/toxin
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseChemical/toxinC57BL/6 wild-type and Nrf2 knockoutMale
Model: Acute cardiotoxicity induced by doxorubicin administration
Dimethyl itaconate reduced doxorubicin induced cardiac injury, lowered RIP3 and oxidative stress markers, halved reactive oxygen species and limited mitochondrial damage, and these benefits were lost in Nrf2 knockout mice.
Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.
